A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable ...

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in ...

The event will be moderated by Kirk Shepard, M.D., PDS Biotech’s Chief Medical Officer. A live question and answer session will follow the formal presentations. Date: Tuesday, June 17, 2025 Time: 12 p ...

Alvotech and Dr. Reddy’s Enter into collaboration to co-develop biosimilar candidate to Keytruda® (pembrolizumab).

A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a brain ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

ASCO Data Shows New Therapy Delays Breast Cancer Progression and May Improve Quality of Life for Women with Hormone ...

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, ...

Dr. Jared Weiss walks patients through the therapeutic potential viability of intratumoral therapies among those with lung ...

Merck secures U.S. Patent Office backing in its legal battle with Halozyme over Keytruda's injectable version. Read more here ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that ...